Pablo Iruzubieta

Dr. Pablo Iruzubieta

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2023 in European Journal of Neurology
Verified
Journal Article
Closed access
PIPablo Iruzubieta
Pablo Iruzubieta
DPDavid Pellerin
David Pellerin
ABAlberto Bergareche
Alberto Bergareche
IAInés Albajar
Inés Albajar
EMElisabet Mondragón
Elisabet Mondragón
JRJavier Ruiz‐Martínez
Javier Ruiz‐Martínez

2 August 2023 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
ÁBÁlvaro Beltrán-Corbellini
Álvaro Beltrán-Corbellini
MRMaría Romeral-Jiménez
María Romeral-Jiménez
PMPablo Mayo
Pablo Mayo
IRIrene Sánchez-Miranda Román
Irene Sánchez-Miranda Román
PIPablo Iruzubieta
Pablo Iruzubieta
AGAntonio Gil-Nagel
Antonio Gil-Nagel

1 April 2025 in Neurology Genetics
Verified
Journal Article
Open access
SCShihan Chen
Shihan Chen
CACatherine Ashton
Catherine Ashton
RSRawan Sakalla
Rawan Sakalla
GCGuillemette Clement
Guillemette Clement
SPSophie Planel
Sophie Planel
RPRoberta La Piana
Roberta La Piana
GAA-FGF14 ataxia (SCA27B) is a recently reported late-onset ataxia caused by a GAA repeat expansion in intron 1 of the FGF14 gene. After the clinical observation of superior cerebellar peduncle (SCP) involvement in some affected patients, we sought to verify the prevalence of this finding in our cohort and 4 additional independent cohorts of patients with SCA27B. We performed a retrospective review of the brain MRI scans of a total of 87 patients (median age at MRI 69 years; range 28-88 years) from different independent cohorts to assess the presence of SCP involvement, defined as abnormally high T2 signal along the SCP tract. We observed SCP involvement in 52 patients (52/87; 59.8%) from all the cohorts combined. The finding was replicated at rates ranging from 50% to 62.8% in the cohorts taken separately. SCP involvement in SCA27B is frequent. Its detection may facilitate the diagnostic process of patients with SCA27B.

25 January 2021 in Histochemistry and Cell Biology
Verified
Journal Article
Closed access
PDF file
PIPablo Iruzubieta
Pablo Iruzubieta
TCTomás Castiella
Tomás Castiella
EMEva Monleón
Eva Monleón
CBCarmen Berga
Carmen Berga
GMGuillermo Muñoz
Guillermo Muñoz
CJConcepción Junquera
Concepción Junquera

2 July 2019 in Gastric Cancer
Verified
Journal Article
Closed access
PDF file
PIPablo Iruzubieta
Pablo Iruzubieta
MARTA MONZONMARTA MONZON
MARTA MONZON
TCTomás Castiella
Tomás Castiella
TRTeresa Ramírez
Teresa Ramírez
CJConcepción Junquera
Concepción Junquera

16 September 2024 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
MZMónica Zufiría
Mónica Zufiría
OPOihane Pikatza-Menoio
Oihane Pikatza-Menoio
MGMaddi Garciandia-Arcelus
Maddi Garciandia-Arcelus
XBXabier Bengoetxea
Xabier Bengoetxea
AJAndrés Jiménez
Andrés Jiménez
Sonia Alonso-MartinSonia Alonso-Martin
Sonia Alonso-Martin
Amyotrophic Lateral Sclerosis (ALS) is a multisystemic neurodegenerative disorder, with accumulating evidence indicating metabolic disruptions in the skeletal muscle preceding disease symptoms, rather than them manifesting as a secondary consequence of motor neuron (MN) degeneration. Hence, energy homeostasis is deeply implicated in the complex physiopathology of ALS and skeletal muscle has emerged as a key therapeutic target. Here, we describe intrinsic abnormalities in ALS skeletal muscle, both in patient-derived muscle cells and in muscle cell lines with genetic knockdown of genes related to familial ALS, such as TARDBP (TDP-43) and FUS. We found a functional impairment of myogenesis that parallels defects of glucose oxidation in ALS muscle cells. We identified FOXO1 transcription factor as a key mediator of these metabolic and functional features in ALS muscle, via gene expression profiling and biochemical surveys in TDP-43 and FUS-silenced muscle progenitors. Strikingly, inhibition of FOXO1 mitigated the impaired myogenesis in both the genetically modified and the primary ALS myoblasts. In addition, specific in vivo conditional knockdown of TDP-43 or FUS orthologs (TBPH or caz) in Drosophila muscle precursor cells resulted in decreased innervation and profound dysfunction of motor nerve terminals and neuromuscular synapses, accompanied by motor abnormalities and reduced lifespan. Remarkably, these phenotypes were partially corrected by foxo inhibition, bolstering the potential pharmacological management of muscle intrinsic abnormalities associated with ALS. The findings demonstrate an intrinsic muscle dysfunction in ALS, which can be modulated by targeting FOXO factors, paving the way for novel therapeutic approaches that focus on the skeletal muscle as complementary target tissue.